Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder

PHASE4RecruitingINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

May 14, 2025

Primary Completion Date

July 1, 2029

Study Completion Date

July 1, 2029

Conditions
Premenstrual Dysphoric Disorder (PMDD)
Interventions
DRUG

sertraline 50 mg daily

The intervention will be in the form of an oral pill, taken daily, from the day of positive urine ovulation test result until the day of menses onset.

DRUG

Placebo Oral Tablet

The placebo oral tablet will be of the same shape, color, and manufacturer as the sertraline 50 mg oral tablets. Tablet will be taken daily, from the day of positive urine ovulation test result until the day of menses onset.

Trial Locations (2)

21205

RECRUITING

Reproductive Mental Health Center, Baltimore

22903

RECRUITING

University of Virginia, Charlottesville

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Johns Hopkins University

OTHER